We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immunodiagnostic Systems Holdings Plc | LSE:IDH | London | Ordinary Share | GB00B01YZ052 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 378.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMIDH
RNS Number : 6449A
Immunodiagnostic Systems Hldgs PLC
03 June 2021
3 June 2021
Immunodiagnostic Systems Holdings plc
Additional Listing to Correct Historical Discrepancy
Immunodiagnostic Systems Holdings plc ("IDS" or the "Company") (LSE: IDH) today announces that an application has been made to the London Stock Exchange for the admission of 102,674 ordinary shares of 10p each ('Ordinary Shares') in IDS in order to correct a historical discrepancy between its issued share capital and the share capital recorded as having been admitted to trading on AIM.
On 10 May 2010, IDS announced the issue and allotment of 2,674 Ordinary Shares to satisfy an exercise of options and on 29 June 2011 IDS announced the issue and allotment of 100,000 Ordinary Shares to satisfy an exercise of options. In both cases a listing application was not submitted due to an administrative oversight and therefore 102,674 Ordinary Shares were not admitted to trading on AIM at that time. It is expected that the 102,674 Ordinary Shares will be admitted to trading on 8 June 2021.
No new Ordinary Shares have been issued or allotted and IDS confirms that its issued share capital remains unchanged at 28,784,097 Ordinary Shares as at 2 June 2021 (excluding 627,078 IDS Shares held in treasury).
For further information please contact:
Immunodiagnostic Systems Holdings plc Tel : +44 (0)191 5190660
Paul Martin, Group Finance Director
Peel Hunt LLP Tel : +44 (0)207 418 8900
James Steel
Victoria Erskine
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ALSUUUBRANUNRAR
(END) Dow Jones Newswires
June 03, 2021 02:00 ET (06:00 GMT)
1 Year Immunodiagnostic Systems Chart |
1 Month Immunodiagnostic Systems Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions